Event Outline
This exciting CDDF Workshop will address how best to deploy smarter cancer clinical trials and use Real World Evidence (RWE) studies to deliver innovation and achieve better outcomes for cancer patients. It brings together key leaders in this rapidly developing field from a scientific, clinical, patient and regulatory affairs perspective. A key emphasis of the entire workshop is “What Really Matters” implementing proportionate, risk based approaches in trial design and conduct.
We will focus on turning “Data into Decisions” and emphasise the importance of implementing pragmatic approaches in cancer clinical trials and use of RWE in this rapidly revolving field. Ensuring pragmatism while driving innovation will be one of the key elements of the workshop.
We will ensure that we place the patient’s opinion front and centre, that we are pragmatic and proportionate in what we present and discuss, and that we also ensure a balanced discussion where all voices are heard. Health data and its deployment will be a significant component of the workshop. Speakers will present some of the latest studies, combined with current and future thinking about how best to define and deploy the latest evidence to ensure that it becomes an integral part of how we drive innovation forward.
Fergus and I are looking forward to welcoming you to Brussels and hosting a discussion that focuses on “What Really Matters”.
Learning outcomes / Meeting objective
- An appreciation of smart clinical trials and RWE studies and how they can both drive innovation and ensure better patient outcomes
- A deeper understanding of using clinical trials and studies and what they can achieve
- An appreciation of the critical importance of cancer patient co-creation and how best to empower patients going forward
- A clear vision of how best we can achieve our goals through the deployment of data – recognising that “byte to bedside” will increasingly be part of our evolving cancer lexicon
Target audience
The target is a multidisciplinary audience of academia representatives, EU and US regulatory bodies (EMA, FDA, National Agencies), the pharmaceutical industry, HTAs, and patient advocates.
Language
The main language of the workshop is English.